Detailed Narrative
Strong Financial Performance and Growth
Suraksha Diagnostic Limited reported a robust financial performance for FY26, with revenue from operations reaching INR3104.1 million, marking a 23.1% year-on-year growth. The company's Q4 FY26 revenue also demonstrated strong momentum, growing 25% YoY to INR822 million. This growth was supported by a stellar three-year revenue CAGR of 17.78% from FY23, showcasing sustained structural growth.
Genomics and Molecular Diagnostics Expansion
The company significantly expanded its genomics and molecular diagnostic capabilities through Suraksha Genomics, which is positioned as a key growth pillar. During the year, Suraksha acquired the first fastest NGS platform, Genexus, in Eastern India, enabling results in 48-72 hours compared to the usual 14-21 days. This enhancement aims for deep penetration in the oncology segment and offers advanced testing capabilities across various domains, including prenatal diagnostics and pharmacogenomics. The genomics vertical recorded an incremental business of INR1 crore in Q4, with a monthly run rate of INR35 lakhs.
Technology and Clinical Capability Enhancements
Suraksha continued to invest in technology and clinical capabilities, signing an MoU with IIT Kharagpur for AI-driven Alzheimer's detection. The company also established the first high-end MRI training center and introduced the latest automation from Roche in its pathology labs, increasing performance threefold. A significant development was the integration of next-generation 1.5T helium-free MRI technology at Calcutta Medical College, enhancing diagnostic capabilities with zero helium dependency.
Network Expansion and Regional Strategy
The company expanded its network to 68 centers by March 26, including 2 new hub centers, 11 spoke centers, and 3 centers under the PPP model. For FY27, Suraksha plans to add 14 new centers, including three new hubs and eight asset-light spoke centers within West Bengal, and specialized hub centers in Bihar, Tripura, and Jharkhand. This multi-state expansion aims to transition Suraksha into a comprehensive regional player beyond its traditional strongholds.
Profitability and Margin Dynamics
FY26 blended EBITDA margin stood at 31.73%, yielding an estimated total EBITDA of INR985 million. However, the FY26 EBITDA margin saw a slight decline to 31.8% from 33.8% in FY25, primarily due to the ramp-up of new centers and pre-operative expenses. Mature centers continue to deliver strong EBITDA margins of 36-37%. Management expects EBITDA margins to stabilize at around 33% in FY27 and reach 35% in the mid-term as new centers mature.
Patient Volume and Revenue Mix
In FY26, Suraksha served 1.37 million patients and performed 8.16 million clinical tests across its network. The revenue per patient increased to INR2,264, reflecting a shift towards specialized diagnostics and advanced radiology. The revenue mix was diversified, with Pathology contributing 48.85%, Radiology 44.26%, and doctor consultancy/polyclinic ecosystem 6.89% of operational revenue. Patient growth in Q4 was modest at 1.7%, attributed partly to seasonality and high-value tests.
Capital Expenditure and Future Plans
The company plans a total capex of approximately INR70 crores for FY27 to support the addition of five hubs and eight spokes. This investment is part of the strategic focus on expanding its footprint across eastern and northeastern India, systematically replicating its high-margin operating model. The company aims to reach 100 centers by FY28, with 14 centers planned for opening in FY27.